What is Opna Bio?
Opna Bio is a biopharmaceutical company based in Lausanne, dedicated to the development of oncology therapeutics. The company's focus on cancer treatments positions it within a critical and rapidly evolving area of medical research and development. This strategic focus aims to address unmet needs in cancer care through innovative therapeutic approaches.
How much funding has Opna Bio raised?
Opna Bio has raised a total of $38M across 1 funding round:
Series A
$38M
Series A (2022): $38M with participation from Menlo Ventures, Longitude Capital, and Northpond Ventures
Key Investors in Opna Bio
Menlo Ventures
Menlo Ventures is a venture capital firm that invests in early and growth-stage technology companies across various sectors, including frontier tech, often taking board roles and partnering with founders through multiple stages of scale.
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions companies, aiming to help innovators scale and improve patient care.
Northpond Ventures
Northpond Ventures is dedicated to advancing science and technology to create significant impacts on humanity, focusing on identifying and supporting breakthrough innovations and entrepreneurial ventures in the scientific landscape.
What's next for Opna Bio?
The substantial enterprise-level funding, including the recent major strategic investment, signals a pivotal growth phase for Opna Bio. This capital infusion is expected to accelerate the company's research and development pipeline, potentially enabling further clinical trials, expanding its therapeutic portfolio, and strengthening its market presence in the competitive oncology landscape. The company is poised to leverage this backing to advance its mission of developing novel cancer treatments.
See full Opna Bio company page
